Literature DB >> 11781422

Predictors of functional disability and mortality after status epilepticus.

J Claassen1, J K Lokin, B-F M Fitzsimmons, F A Mendelsohn, S A Mayer.   

Abstract

The authors identified predictors of functional disability and mortality after status epilepticus in a multivariate analysis of 83 episodes in 74 patients. Twenty-one percent (14/85) of episodes were fatal. Increased age (OR = 1.1; 95% CI, 1.0 to 1.1) and acute symptomatic seizures (OR = 6.0; 95% CI, 1.2 to 30.3) were predictors of mortality. Functional outcome at discharge deteriorated in 23% (16/69) of nonfatal episodes. Increased length of hospitalization (OR = 1.04; 95% CI, 1.0 to 1.1) and acute symptomatic seizures (OR = 3.9; 95% CI, 1.0 to 14.7) were predictors of functional disability.

Entities:  

Mesh:

Year:  2002        PMID: 11781422     DOI: 10.1212/wnl.58.1.139

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

Review 1.  Seizure prediction and its applications.

Authors:  Leon D Iasemidis
Journal:  Neurosurg Clin N Am       Date:  2011-10       Impact factor: 2.509

Review 2.  The utility of EEG, SSEP, and other neurophysiologic tools to guide neurocritical care.

Authors:  Eric S Rosenthal
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Prolonged coma from refractory status epilepticus.

Authors:  Saqib I Dara; Lori A Tungpalan; Edward M Manno; Vivien H Lee; Kevin G Moder; Mark T Keegan; Jimmy R Fulgham; Daniel R Brown; Keith H Berge; Francis X Whalen; Tuhin K Roy
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

4.  Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.

Authors:  Christa B Swisher; Meghana Doreswamy; Krista J Gingrich; James J Vredenburgh; Brad J Kolls
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

5.  Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.

Authors:  Jason McMullan; Comilla Sasson; Arthur Pancioli; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

6.  Evaluation of STESS, mRSTESS, and EMSE to Predict High Disability and Mortality at Hospital Discharge in Ecuadorian Patients with Status Epilepticus.

Authors:  Dannys Rivero Rodríguez; Claudio Scherle Matamoros; Kimberly Sam; Daniela DiCapua Sacoto; Nelson Maldonado Samaniego; Yanelis Pernas
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

7.  Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study.

Authors:  Vincent Alvarez; Jong Woo Lee; M Brandon Westover; Frank W Drislane; Jan Novy; Mohamed Faouzi; Nicola A Marchi; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

8.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

9.  Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus.

Authors:  Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

10.  Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy.

Authors:  Andrea O Rossetti; Giancarlo Logroscino; Tracey A Milligan; Costas Michaelides; Christiane Ruffieux; Edward B Bromfield
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.